Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eli Lilly has declared that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP), has issued a positive opinion for the use of Alimta (pemetrexed for injection) as monotherapy for the maintenance treatment of metastatic non-small cell lung cancer (NSCLC).
Subscribe to our email newsletter
Following the positive report by CHMP, Lilly has also filed for approval of ‘pemetrexed’ in the same indication with the FDA.
In the European Union and US, pemetrexed is already approved, in combination with cisplatin, as a first-line treatment for locally advanced or metastatic nonsquamous NSCLC for patients. It is indicated as a single agent for the second line treatment of patients with locally advanced or metastatic nonsquamous NSCLC after prior chemotherapy.
Richard Gaynor, Vice President of Cancer Research and Global Oncology platform leader for Lilly, said: This recommendation from the CHMP is encouraging and it brings us one step closer to offering a tailored treatment option that can potentially extend lives for non-small cell lung cancer patients with nonsquamous histology.